Cargando…

Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease

The involvement of DNA damage and repair in aging processes is well established. Aging is an unequivocal risk factor for chronic neurodegenerative diseases, underscoring the relevance of investigations into the role that DNA alterations may have in the pathogenesis of these diseases. Consistently, e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milanese, Chiara, Cerri, Silvia, Ulusoy, Ayse, Gornati, Simona V., Plat, Audrey, Gabriels, Sylvia, Blandini, Fabio, Di Monte, Donato A., Hoeijmakers, Jan H., Mastroberardino, Pier G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062587/ https://www.ncbi.nlm.nih.gov/pubmed/30050065 http://dx.doi.org/10.1038/s41419-018-0848-7

Ejemplares similares

Gender biased neuroprotective effect of Transferrin Receptor 2 deletion in multiple models of Parkinson’s disease
por: Milanese, Chiara, et al.
Publicado: (2020)

Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson’s Disease
por: Sepe, Sara, et al.
Publicado: (2016)

Inflammation promotes synucleinopathy propagation
por: Kim, Tae-Kyung, et al.
Publicado: (2022)

Potential therapeutic effects of polyphenols in Parkinson’s disease: in vivo and in vitro pre-clinical studies
por: Giuliano, Claudio, et al.
Publicado: (2020)

Sphingolipid changes in Parkinson L444P GBA mutation fibroblasts promote α-synuclein aggregation
por: Galvagnion, Céline, et al.
Publicado: (2022)

Parkinson’s Disease in Women and Men: What’s the Difference?
por: Cerri, Silvia, et al.
Publicado: (2019)

A perspective on DNA damage-induced potentiation of the pentose phosphate shunt and reductive stress in chemoresistance
por: Milanese, Chiara, et al.
Publicado: (2020)

Glucocerebrosidase Defects as a Major Risk Factor for Parkinson’s Disease
por: Avenali, Micol, et al.
Publicado: (2020)

GBA Mutations Influence the Release and Pathological Effects of Small Extracellular Vesicles from Fibroblasts of Patients with Parkinson’s Disease
por: Cerri, Silvia, et al.
Publicado: (2021)

Peripheral-Central Neuroimmune Crosstalk in Parkinson's Disease: What Do Patients and Animal Models Tell Us?
por: Fuzzati-Armentero, Marie Therese, et al.
Publicado: (2019)

Glucocerebrosidase Involvement in Parkinson Disease and Other Synucleinopathies
por: Almeida, Maria do Rosário
Publicado: (2012)

Linking the Endoplasmic Reticulum to Parkinson’s Disease and Alpha-Synucleinopathy
por: Colla, Emanuela
Publicado: (2019)

Evidence of Inflammation in Parkinson’s Disease and Its Contribution to Synucleinopathy
por: Lai, Thuy Thi, et al.
Publicado: (2022)

Alpha-Synuclein Targeting Therapeutics for Parkinson's Disease and Related Synucleinopathies
por: Menon, Sindhu, et al.
Publicado: (2022)

Neuroinflammation and Immune Changes in Prodromal Parkinson’s Disease and Other Synucleinopathies
por: Terkelsen, Miriam Højholt, et al.
Publicado: (2022)

Senescence and impaired DNA damage responses in alpha-synucleinopathy models
por: Yoon, Ye-Seul, et al.
Publicado: (2022)

Neuroprotective and Symptomatic Effects of Cannabidiol in an Animal Model of Parkinson’s Disease
por: Giuliano, Claudio, et al.
Publicado: (2021)

Dysregulated Lipid Metabolism and Its Role in α-Synucleinopathy in Parkinson’s Disease
por: Alecu, Irina, et al.
Publicado: (2019)

Neuroglial Senescence, α-Synucleinopathy, and the Therapeutic Potential of Senolytics in Parkinson’s Disease
por: Miller, Sean J., et al.
Publicado: (2022)

Long‐lasting pathological consequences of overexpression‐induced α‐synuclein spreading in the rat brain
por: Rusconi, Raffaella, et al.
Publicado: (2018)

Interneuronal In Vivo Transfer of Synaptic Proteins
por: Klinkenberg, Michael, et al.
Publicado: (2023)

Pathological looping in the synucleinopathies: investigating the link between Parkinson’s disease and Gaucher disease
por: Kinghorn, Kerri J.
Publicado: (2011)

α-Synuclein Transgenic Drosophila As a Model of Parkinson's Disease and Related Synucleinopathies
por: Mizuno, Hideya, et al.
Publicado: (2010)

Role of α- and β-Synucleins in the Axonal Pathology of Parkinson’s Disease and Related Synucleinopathies
por: Sekigawa, Akio, et al.
Publicado: (2015)

Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies
por: Ebrahimi-Fakhari, Darius, et al.
Publicado: (2013)

Reduced Cytosolic Calcium as an Early Decisive Cellular State in Parkinson’s Disease and Synucleinopathies
por: Betzer, Cristine, et al.
Publicado: (2018)

Correlations of Neuropsychological and Metabolic Brain Changes in Parkinson's Disease and Other α-Synucleinopathies
por: Trošt, Maja, et al.
Publicado: (2019)

Synucleinopathy-associated pathogenesis in Parkinson’s disease and the potential for brain-derived neurotrophic factor
por: Miller, Kathryn M., et al.
Publicado: (2021)

Peripheral synucleinopathy in Parkinson disease with LRRK2 G2385R variants
por: Yang, Jing, et al.
Publicado: (2021)

ATPase Thorase Deficiency Causes α-Synucleinopathy and Parkinson’s Disease-like Behavior
por: Gao, Fei, et al.
Publicado: (2022)

Profiling the Biochemical Signature of GBA‐Related Parkinson's Disease in Peripheral Blood Mononuclear Cells
por: Avenali, Micol, et al.
Publicado: (2021)

Gaucher Disease and the Synucleinopathies
por: Hruska, Kathleen S., et al.
Publicado: (2006)

The Synucleinopathies: Twenty Years On
por: Goedert, Michel, et al.
Publicado: (2017)

Surgical Management of Synucleinopathies
por: Sriram, Sai, et al.
Publicado: (2022)

Neuron-to-neuron α-synuclein propagation in vivo is independent of neuronal injury
por: Ulusoy, Ayse, et al.
Publicado: (2015)

A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease
por: Morelli, Micaela, et al.
Publicado: (2012)

Rotigotine is safe and efficacious in Atypical Parkinsonism Syndromes induced by both α-synucleinopathy and tauopathy
por: Moretti, Davide Vito, et al.
Publicado: (2014)

An Enriched Environment Ameliorates Oxidative Stress and Olfactory Dysfunction in Parkinson’s Disease with α-Synucleinopathy
por: Wi, Soohyun, et al.
Publicado: (2018)

Opportunities and challenges of alpha-synuclein as a potential biomarker for Parkinson’s disease and other synucleinopathies
por: Magalhães, Pedro, et al.
Publicado: (2022)

PPARs and Their Neuroprotective Effects in Parkinson’s Disease: A Novel Therapeutic Approach in α-Synucleinopathy?
por: Pérez-Segura, Isaac, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gugnu79t9utua7hgdaglu3527k